Advancing Cancer Research and Innovation through Collaboration at GCRIS 2026

We're taking a deep dive into the upcoming Global Cancer Research and Innovation Symposium (GCRIS) in this latest episode of Value-Based Voices.

Join GCRIS Scientific Co-chairs Stan Skrzypczak, MS, MBA, Managing Partner, 5 Prime Life Science Consulting, and Nick Sarlis, MD, PhD, FACP, Chief Medical Officer, Cleara Biotech, as they talk with GCRIS Co-chair Matt Vossler, Managing Director, DSG Global, about the groundbreaking science, innovative drug development, and collaborative ecosystems that are reshaping oncology. 

Hear about: 
- the rise of "biotech 2.0" 
- the complexity of bringing new therapies to market
- strategies to accelerate drug development cycles and regulatory pathways
- what the future holds for researchers and the investors eager to capitalize on emerging science
- why GCRIS and its collaborative, unscripted conversations are needed now more than ever

Whether you’re in research, investment, or policy, this episode is essential listening for anyone who wants to stay ahead of the curve in cancer innovation. 

Request your invitation to attend the GCRIS taking place October 5-6, 2026 in New York City: https://avbcc.org/gcris/

********************************************
Resources & Links
• Swim Across America: https://www.swimacrossamerica.org

Contact Value-Based Voices

- Follow AVBCC on LinkedIn  

- View our podcast lineup 

- Contact us at info@avbcc.org

Thanks for listening! 

Transcript

Introduction to the importance of the GRIS Conference in the world of cancer research

Speaker 2 0:00

Welcome to Value-Based Voices, a podcast from the Association for Value-Based Cancer Care. Each episode dives into the shifting terrain of cancer care in the United States, exploring what value means in today's clinical policy and patient-centered environments. Our mission is to spark informed dialogue, promote transparency, and equip every stakeholder from providers to payers to patients with the insight they need to navigate cancer care with clarity, confidence, and purpose.

Introduction of the host and background on the conference

Speaker 2 0:57

My name is Matt Vossler, Managing Director of DSG, Executive Global Search Company. I'm the co-chair of the Global Cancer Research and Innovation Symposium, and I'll be your host for the episode.

History of the organization and the importance of supporting young researchers

Speaker 2 1:12

With me this morning are Gris scientific co-chairs, Dr. Nicholas Sarlis, Chief Medical Officer, Clara Biotech, and Stan Skrzypczak, managing partner, Five Prime Science Consulting. Welcome.

Speaker 1:27

Thank you, Mr.

Speaker 2 1:28

Looking forward to a lively conversation and talk about the event that's coming up and the anticipation we have and the excitement with the amazing array of talent that we have assembled. Let's get into a little bit about the history of GRIS. And you know, I have to begin with Bert, who has just been incredible in terms of our board of directors with Swim Across America, as well as the founder and executive director of the Association for Value-Based Cancer Care. This idea for the GRIS event really grew up a couple of years ago out of discussions that Bert had with a number of our key swim investigators, principally Jedd Wolchok. And what we really were looking for was a platform to highlight the amazing work that our researchers are doing in the labs all across the country, as well as talk about the model, which is very unique in terms of going in and identifying young investigators and physician scientists

Focus on funding and the role of charitable initiatives

Speaker 2 2:38

and funding their programs, generally funding high-risk, high reward types of programs that normally would not be on the radar with FDA. But let me step back a little bit with Swim Across America. It's an organization that we started coming up on 40 years ago, swimming across bodies of water throughout the United States to raise money for cancer research. The model really was built at Memorial Sloan Kettering to focus on just that, young investigators and physician scientists. They had said to us even back in the 90s, this was an area that was in great need of support. We just weren't getting the dollars and the resources in to fund these young investigators. Today, now more than ever, it's a critical, critical time to be funding the young talent that we have in this country and keeping them here as well. So we really want to highlight a lot of the important sessions and topics that we'll be getting into with GRIS. And you know, today really take a deep dive into why now. Why is GRIS so important? What is happening in the environment that we see that need us to really make this a successful event and continue that critical funding? Love to get your input, Stan.

Enhancing innovation among researchers, governments, and regulators

Speaker 1 4:04

Yeah, so thanks so much, uh Matt. And it's really a pleasure to be here and be a part of the uh the GRIS family. Um, I don't think that there's ever been a greater time to think about innovation and really how to continue to propel the work that we've been doing in cancer research over the last decades than to bring together the right stakeholders. And the right stakeholders aren't just the pharma, aren't just the researchers, but we've seen it also includes our policymakers and our regulators. And even if you go further deeper uh into that uh uh sphere, uh our investors. And how are investors now thinking about this potentially new world order uh that we're faced with now? So while we've seen sort of changes that have happened in the past, I think the time is now to look at how the three of these legs of the tripod can really work together, uh, come up with innovative solutions and really continue to advance uh innovation and technology uh in the U.S., in particular for cancer research.

Speaker 2 5:05

Yeah, great. And you know, the funding gap, obviously, with all that's happening with NIH, uh you know, we're really seeing a need to keep this line of support open. Could you talk to that?

Speaker 5:19

Absolutely, Matt, and and I second every word that uh Stan said. In fact, it is indeed my distinct honor as a physician scientist myself, and having kind of uh uh had a career both in the academic world and and in the biotech pharma world, uh, we see these very complex problems and challenges that uh uh have defied solutions uh in in years and decades. And the only way to really resolve these problems or at least start visioning these solutions is bringing people together in an open environment uh where they can talk to each other and and and communicate with each other with no silos and no compartments. And I think this is what uh this meeting uh is is all about. And and I will basically expand the abbreviation again because it's global, albeit US focused, obviously, cancer research innovation symposium. And I think you know the um uh the title says everything. So you have the pillars that um are the academic investigators, the regulators, um, the investors, uh, all the ecosystem. And in fact, it stands, as you mentioned, Matt, on the pediment of uh venture philanthropy.

Speaker 2 6:35

Yeah. And it's exactly right. It it's just a critical time for that approach from a philanthropic perspective as well as from a science-based perspective. And the investor world has to look at the importance of funding entire programs and moving programs forward. And let's talk about the science. I mean, what's what's going on? I keep hearing that this is the best time, probably in the history of mankind, where we've got incredible advances. Um, the technology, the talent, the science. Talk to that, Stan,

Technological developments and their potential to accelerate drug development

Speaker 2 7:11

if you can.

Speaker 1 7:11

Aaron Powell Yeah, sure. So um I think that uh a couple of very interesting developments are happening in parallel that make for a perfect storm. One, you've got the tools that you need uh to build uh the types of next-gen drugs that we're considering. We're seeing advances in single-cell sequencing, in spatial transcriptomics, and whole genome sequencing done at scale that unlock uh a variety of different uh understandings of biological pathways. We're also seeing the explosion in AI as a tool that could be used to streamline large, large, massive sets of data uh that could be useful for determining drug resistance pathways. So, you know, you look at those two factors and then you see how the drug development cycle itself has been uh not necessarily lengthened but shortened. What used to take years to try to think through uh the right types of uh patient cohorts, the right type of study design, you know, has been abbreviated dramatically in the last uh uh several years by uh advances in AI. So I think, you know, when you look at that confluence, it's an exciting time. We're seeing some very interesting activity, um, in particular in the Car T space. Uh I think over the last year there's been over 10 billion, 10 with a B dollars of acquisitions for in vivo car T's, which is an area we're gonna explore in uh day one of our GRIS session. Um I think some of the other advances that we're seeing on other modalities is equally interesting, thinking about moving beyond what we historically considered checkpoint inhibition. Uh, how are we using alternative modes of interventions to really amplify what we see as early responses? So the science is there, the tools are there, now we just gotta bring it together into the drug development paradigm and make it real for patients.

Speaker 2 9:01

Yeah. Yeah. And some are calling this, Nick, uh a biotech 2.0 moment. And this is certainly something that we're we we want to bring out and promote with GRIS and with all the sessions and the people that we have. But I'd love to talk, hear you talk about that biotech 2.0

The concept of "biotechnological revolution" and its challenges

Speaker 2 9:19

moment.

Speaker 9:19

You bet. And what Stan mentioned is that yes, the science has progressed with leaps and bounds, but at the same time, so has the complexity, right? And so um it's not just throwing technology and throwing money to the problem. I think one of the fundamental motivators of actually getting together the the Greece Symposium is that is to bring the stakeholders together to have them cross-understand the complexity and where where are the the core challenges that I think everybody sees from a different angle. It's actually seeing the diamond from its angles. And what have been the lessons learned from one discipline to the other? Uh, perhaps note some of the success stories. Uh, and where these success stories have limitations, talking about uh uh deliverability of CAR T, distribution of CAR T, novel methods for cellular therapies, hitting the ceiling on immunotherapy, and what kind of new modalities do we need? And so we have on one hand a ton of new MOAs, perhaps even more targets that we can handle on an individual basis or even in a big company in a portfolio. And I think we need more communication and more collaboration, and and this is the venue to actually do that, and it's actually a very unique venue because you, you know, most of us go to six uh or a dozen meetings, you know, every year. And um you you kind of hear things from a siloed approach. And I think the Greece Symposium is really unique in bringing the stakeholders with openness and willingness to discuss really the core challenges and start visioning solutions.

Speaker 1 10:49

Yeah, and you know, I think uh Nick, building on that, I think a lot of meetings that I've seen in the past are somewhat siloed in so far as you might have a meeting dedicated to policy, you might have a meeting dedicated to science, you may have a meeting for the investors where they hear about the companies they've invested in or the publicly traded companies discussing uh their most recent earnings. Um, this kind of brings together everyone to address how are we all gonna make this happen? The drug development cycle, how are we gonna make it happen? How are we gonna bring these investments that are being made to patients? How are we gonna make it happen? And then ultimately, how are we gonna move the needle forward with regulators to ensure that the proper pathways are are engendered to really make these uh all things happen for patients? So I I think it's kind of a very unique setting to bring those three together, and that's why I'm particularly excited.

The importance of cross-sector collaboration to improve clinical outcomes

Speaker 2 11:42

Yeah, I've always been impressed with the openness uh of the meeting. And you know, again, I've I've we we all go and do the the the whole list, you know, we just came off of AACR recently and ASCO coming up. Uh this is unique, and to me it is because it's um in terms of the size, in terms of the ability to network and meet some of the key people, um, and really talk uh transparently about what are some of the challenges and what are the things that we need to do to find solutions. Um give me a sense, who who are we targeting? What type of person really is gonna benefit from coming to Griss and experiencing our you know our day and a half? So step back for a second. So this year is unique, as you know. The first half day is really gonna be focused on investors. So um, you know, pharma, biotech, you know, business development and licensing types of executives. We're also gonna be bringing in, you know, uh the venture firms, as well as uh Wall Street analysts, family offices, and really everybody that kind of lives in that ecosystem of early stage or developmental stage um investment in these types of cancer therapeutics. But give me your sense. What why why would I come? Why is this different from an investor's perspective to attend

Interaction strategies between investors and researchers

Speaker 2 13:06

this meeting?

Speaker 1 13:06

Yeah, so uh I think that's one of the reasons why I'm very pleased with working with Nick on this, that uh we've constructed kind of a half day to really be more of the peek into the tent, so to speak, of what's going on with uh some of the MA activity, what's going on with areas that are in need of some innovative solutions, venture philanthropy is an area we're exploring. And then the last area, which I'm very pleased to see, uh, we're able to work with the CZ Biohub and have an exploratory discussion on what they're doing with the Billion Cells Project. I think that's really cutting edge in terms of where the future is, which is ideally what a lot of the investor types really like to you know understand and key in on. You know, day two is really the biopharma day. Now, that's not to say the investment community isn't interested to hear directly from the KOLs that are in the trenches, that are doing the drug development, that are building these uh uh innovative compounds uh about what's going on on day two, but day two is really uh the pharma uh executives that are involved in drug development, portfolio management, IT, or should say AI, IT specialists, and the CROs that are an important element of the ecosystem to bring these forward. So it really is, I think, a little of both for the investment community as well as for the clinicians and for the people that are in the drug development side of the business. Um I think one of the other uh, sort of speak, uh, sessions that I'm very interested to hear is we have three industry leaders uh in the biopharma industry that are gonna be discussing sort of what's sitting on the lap of an executive, a CMO, as you think about uh what it's gonna take to bring what's going on in their uh research and development labs to phase one, to phase two, and then operationalize that. So it's a it's a very interesting meeting for all types that are involved in the drug, uh, the drug development management lifecycle. And I think uh we're closing it today, I think, with uh uh some of the uh swim across America pioneers, Jedd Wolchok, Luis Diaz, uh Andrea Cercek, that have been doing a lot of work and have them explain, hey, this investment was made in my lab years ago. Well, here's what we've done now. So it's really kind of a nice closing of the loop uh for uh what I think is going to be a really provocative and informative day and a half sessions.

Future outlook and opportunities in pharmacology

Speaker 2 15:35

So, Nick, as a as a CMO, uh, you know, really understanding uh the challenges for now for several years that biotech has faced uh from a funding perspective, you know, really from you know trying to move those programs forward in the clinic. Um give us a sense of what what a CMO would be looking for in in this type of meeting uh and and really the types of people that you'd be looking to interact with.

Speaker 16:02

No, absolutely. And and I'll I'll pick up from where Stan uh left on on the rest of the half of the first day and then and the second day, which I think is is really highlighting the science. So you have fairly high-level C-suite uh people, both from Big Pharma and Biotech. And I think we have uh the presentations, but we also have the moderators and the panels and and you know, truly uniquely curated topics that are actually looking at the future. I think the CMR all has become increasingly more complex and challenging because it's not just looking at what is happening in the portfolio or in the asset or in the platform today, but where will these assets or portfolios be three to five years from now, perhaps even a decade from now? I mean, most of us are now living in a 2030 horizon. Um, and and it's not just the current funding, but what kind of funding will one demand and expect uh when you are at the pivotal stage or when when you're making a first in-class or best in class effort to enter the market and persuade regulators and persuade payers and so on and so forth, and eventually have benefit for unmet medical need uh for patients and society at large. And I think this is where uh the crux is. I will also add to add uh the fact that uh we have third-party uh CMOs and CDMOs and CROs that are extremely important in the ecosystem because this is where the operational technology is coming in as well. Uh patient selection for trials, optimization of protocols, preparation of documents. And again, a lot of people feel that this is more tactical, but if you don't do these things with modern technology and current uh look into the future, you're you're you're losing time. And you're losing time on patents, you're losing market um uh reimbursement time, and at the end of the day, patients are waiting for new drugs.

Day two program and the importance of direct dialogue

Speaker 2 17:57

So, really, as as as I talked earlier about the genesis of this of the idea to create this meeting really came from a number of our KOLs who thought that it was important that with all the programs that swim across America, funds across the country. By the way, we have between eight and ten million dollars invested at any given time uh you know in 40 plus institutions that are engaged in in levels of basic research and translational research. It was really critical to them to try to create a meeting where we started talking to each other. We started sharing ideas. I'd love to hear your thoughts on what day two of this meeting really looks like, you know, and how we really try to promote that.

Speaker 18:47

Yeah, so as we already discussed, I think it's uh it's intergroup collaboration uh opportunities. And and you know, obviously every meeting has that, but to just be more specific, as you mentioned, academics um are the innovators, and and in essence, a lot of academic spin-offs become biotech. And so academics and biotech are the innovators, and so we we we do recognize and acknowledge the source of innovation, but I think it's a great meeting for the academics and the biotech leaders to really realize the need for um the appropriateness of funding and that at the end of the month, at the end of the day, uh the market is the crucible of value, right? And and looking at where the vision is going in oncology in the next, I would say, five to seven years, which is basically the horizon that we're operating right now, um, will also focus these academic investigators to enhance the innovation, right? And so it's because innovation doesn't happen in a vacuum, right? And that's how we have MOAs that come and come and go out of favor, so to speak. Uh, what new drugs we need to combine? We can talk about synthetic lethality, about combinations, about sequencing, about things that are becoming more and more important because at this point no one is using at the end of the day monotherapy to cure cancer. So there are a lot of uh a lot of uh uh platforms and ideas that I think this meeting can bring forth and look at strategic insight, both for academia and for biopharma, big pharma, and the funding community.

Participation of junior researchers and communication with leaders

Speaker 2 20:19

Yeah, yeah. And I, you know, and and one of the other thoughts on this meeting as well was to to not only highlight and promote our young investigators, but also have give them the opportunity to meet some of our KOLs. So, for example, last year, you know, we had a great inaugural meeting, and we brought in Tom Lynch from Fred Hutch, you know, we had Steve Rosen from City of Hope, uh Jedd Wolchok, Luis Diaz, uh, you know, many of our top people. Um, you know, I know Larry Norton gave a very rousing uh, you know, uh discussion on what he sees as the values of it of investing in in whole pipelines of programs that are being developed inside our institutions. But I'm just I you know give me a sense. Who who do we have on deck this year? Who are some of the names that uh are gonna wow us and really give our young investigators a chance to meet the people who then potentially become their mentors and you know certainly their main connectors going forward from a career perspective?

Speaker 1 21:26

Yeah, so um I think you've mentioned uh, so to speak, the the the main highlighted individuals that have been with us for quite some time. The the session I'm most interested in is uh the one we have uh uh Jeff Legos from Pfizer, uh who's agreed to uh speak at the round table. That'll be moderated by Skip Burris, uh Sunil Verma from AZ, uh, and uh more recently uh uh Mark Rutstein from Novartis. So now we have three pharmas that uh collectively, from a market cap perspective, uh occupy a tremendous amount of space that we have uh on the agenda floor. So I think that, you know, that that uh that aspect is is particularly interesting. Um on the early stage innovation side, one session we're doing which deals with pediatric oncology is quite interesting. And uh Andrew Kung, who's the uh chair for pediatric oncology at MSK, who I think is trained half the pediatric oncologists in the country, um, is going to be doing an interesting session on what we've learned or what we can learn from pediatric oncology. Case in point, CAR-T were instituted at children's hospital in Philadelphia Pennsylvania. So, you know, we're gonna talk a little bit about uh what's new, what that really cutting edge research field uh is working toward. And then I think we're gonna get involved with corporate partnerships and uh talk a little bit more about uh sort of what's the the ball that's headed in that vein. So uh a number of folks that we brought in are gonna pers gain that perspective on uh enhancing value through corporate partnerships, et cetera. So I think you know we we've got it stacked in a way that speaks to not only the scientific side, that speaks to the drug development side, but also talks to the what I call the business of oncology. So I'm I'm particularly excited to hear the the the discussions all moderated, no slides, uh purposefully done.

Speaker 23:18

Slides get to be a little bit cumbersome and again uh takes away the you know the script that uh folks uh don't necessarily want to come here to hear they want to hear the unmic'd version so I think that uh it should be an engaging uh part of our discussions

Discussion on event organization and its significance

Speaker 23:33

excellent and just to supplement what Stan just said um I I think we have done uh we have put significant effort in mixing the panels in an appropriate way so that you have big pharma and biotech and sometimes even academics talking at the same panel and um as I mentioned you know they see the same diamond from different angles. But I I think also the the couple of the plenary uh session speakers the panelists the moderators the discussants even the audience uh I think one of the things that is unique in this meeting is that they bring without slides unscripted the totality of their experience and that totality of experience is across the ecosystem is from early discovery biology preclinical development all the transition into early clinical from early clinical to late clinical and even um within a class or pipeline selection for what needs to be promoted um or and and and developed in the in the near future so I think it's it's a really unique mixture and I think people will get tremendous value out of this meeting.

Speaker 2 24:34

Yeah excellent and of course we've got the venue which is just you know um historic historic and you know just incredible to be you know in for the the day and a half or two days that we're there. There is a pool there and uh we're not requiring however that our participants swim any laps uh as it is a swim across America uh you know partnered event. So location wise as well I I think that really draws um certainly from the greater New York and and New Jersey area but also beyond. I mean we've had people flying in from all over the country all over the world to attend this and it's just a beautiful time to be in New York City uh in early October.

Speaker 1 25:16

Absolutely I find myself uh taking a quick walk through Central Park and seeing the fall colors which uh living in California uh we miss a little bit of that uh you know flavor and color uh on the West Coast but uh I always come back home and see the uh uh Central Park and uh uh the the fall foliage so that's also a nice uh

The atmosphere and notable places in New York and event preparations

Speaker 1 25:35

additional indeed uh actually uh looking out the window from the New York Athletic Club is a nice visual uh interlude from the sessions uh which we try to make them conversational without the data data dumps and no slides but but still it's nice to look at Central Park from the window.

Speaker 2 25:51

Yeah it really is it's become one of my favorite meetings uh of all the ones that I attend. You know let's talk about um sponsors let's talk about uh partners uh for the organization and uh who we really think should come in and and and play a role here and help us put on the event and who really can benefit you know from having their name associated with us, having signage um you know give us a sense of of you know some of those players at this point if you can.

Speaker 1 26:20

One of the things that we've done with this meeting is we've leveraged the vast history, the 15 year history of A V B C C and not only the pharmacos that have been involved on A V B C C and the market access commercial side but also um literally the academic and large community centers between let's say Duke to Dana Farber. I mean that entire East Coast corridor serves as a rich uh ground for uh the clinicians that are in the trenches, that are doing clinical trials that are actively involved with pharma and I think that the audience that we're bringing in kind of allows for that type of meaty and juicy discussion when it comes to how to advance clinical trials. You have day two which is uh you know more involved on that side uh the investment community it's right here in New York so you know it's not a full day it's a half day so investors can get to their early meetings take a look at the big board and then come over around lunchtime and and really engage with straight from the horse's mouth people that are in the trenches, that know what's going on that are at the real forefront of the investment community as well as the clinical community. So I think the two audiences would be the mostly the the people that are engaged in drug development from A to Z, entire ecosystem, the investment community that is always looking for that understanding and you know I think as Nick mentioned the totality of discussions that only come not from reading a report or by hearing an analyst but from really you know talking to the people that are in the trenches. So I I think it's just a unique opportunity for both audiences.

Speaker 27:58

Yeah I mean everybody who needs the Holy Grail so to speak with the strategic clarity we're all inundated with data and we're just throwing more technology and to some degree more money in the ecosystem and and we still do not have the strategic foresight that we need to really see the path to its completion and successful market entry and benefit to patients. And I think this is where

The importance of participation and idea exchange among all participants

Speaker 28:23

the the the stakeholders that are going to attend this meeting are going to get the value because at the end of the day there is a transversal emergence of new ideas and new collaborations and new discussions and new funding that may come from this. And so it's uh I would also posit that the analysts from the financial world my hands is that they're gonna come to all of day two because the analysts are very hungry to learn from uh the horse's mouth so to speak and and uh they will be uh vigilant to see what is being discussed in there um because again this is something that is not you know it's it's not a 5,000 people meeting and so they will have interest to see where uh their financial houses should really be putting money in.

Speaker 2 29:06

Yeah no it it it really is and it's as I said the intimacy of the venue of the ability to to walk be three you know between meetings and it it is jam-packed you know I I I have been told that is this is a uh a a meeting certainly in terms of the quality of the content in the speakers and participants uh it's also on steroids because we really really pack a lot in and so I tell people when they're attending be be ready to to stay active and and don't uh don't take any downtime because you don't know who you're gonna bump into in the hallway or you know have a chance to to meet perhaps at one of the uh uh the meals or or kind of like social gatherings that we have uh and and to that end I know we conclude on uh Monday evening with a poster walk which also uh is exciting from my perspective because I know we want to really try to highlight some of the young investigators inside the Swim Across America network but it's also um again gives that that chance for for for those young physician scientists and investigators to meet the top people in the world and also we we give them a chance to really show off their work and show off their science. Stan, I know you've been a big big proponent of doing this.

Investment opportunities and collaboration with the academic community

Speaker 1 30:24

Yeah absolutely so you know um so we have the big banks that have the analysts that are really looking more on the MA space and sort of what's going on in in that whole sphere but we're also targeting the the VC market and to the VCs you want to find out what's up and coming, what's next, what are those unique opportunities, maybe not to the extent that the analysts of the big banks are doing, but to the extent that you could hear from I think there's over 200 investigators that have been part of Swim Across America over the years and they're doing amazing work. The work that comes out of these academic centers frequently traverses and becomes the next you know new co, the next investment opportunity. That's the place that a lot of these neat finds can be had the the venture capital market can get a chance to not only hear the macro picture, but can also interact with emerging scientists, with emerging ideas, emerging technology. And that's what kind of funnels that part of the investment ecosystem so I'm a big proponent not only on day one but day two to have the same posters up and giving people that maybe could not make day one a second bite at the apple so to speak of hearing from these investigators that are doing amazing work funded by Swim Across America.

Speaker 31:43

Yeah. And indeed there are two types of poster walks right the first one is the classic poster walk that we do in in the major meetings or even the smaller meetings that are focused on the science. And then there is the poster walks that people do in research days in biotech and pharma but this one is different because you have the opportunity to not only have the mentors and people that are not your direct mentors but mentors of the entire ecosystem people that are giving the plenary sessions at ASCO NAACR and ESMO come and look and discuss your poster and the funding community. So it's it's I would say the poster walk of the third kind.

Speaker 2 32:19

Really really excited for the event coming up honored to be co-chair with both of you and you know the amazing work that you have all done in terms of the cancer space and really moving the science and and moving the opportunities for patients and you know to extend lives to save lives

Conclusion and invitation to participate in upcoming events

Speaker 2 32:39

to improve lives it's what it's all about and both of you are just incredible leaders in the in the field and we're just delighted to have you here and I'm honored to be a co-chair with you. This wraps up the episode of Value Based Voices brought to you by the Association for Value Based Cancer Care. Thank you Nick and Stan for sharing your your thoughts your insights and certainly your enthusiasm about the cancer research space in general and certainly the upcoming meeting. Stay tuned for our episodes that spotlight the voices and future of oncology cancer care and cancer research